TMDX
Transmedics Group Inc
$
119.170
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
122.970
Open
122.970
VWAP
118.45
Vol
960.71K
Mkt Cap
4.07B
Low
115.210
Amount
113.79M
EV/EBITDA(TTM)
33.87
Total Shares
32.94M
EV
4.12B
EV/OCF(TTM)
23.14
P/S(TTM)
8.23
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
184.70M
+17.37%
0.850
-7.61%
170.61M
+18.86%
0.760
+8.57%
156.34M
+28.54%
0.396
+108.63%
Estimates Revision
The market is revising Upward the revenue expectations for TransMedics Group, Inc. (TMDX) for FY2025, with the revenue forecasts being adjusted by 0.27% over the past three months. During the same period, the stock price has changed by -6.36%.
Revenue Estimates for FY2025
Revise Upward
+0.27%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+15.3%
In Past 3 Month
Stock Price
Go Down
-6.36%
In Past 3 Month
11 Analyst Rating
21.26% Upside
Wall Street analysts forecast TMDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMDX is 144.50 USD with a low forecast of 115.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
2 Hold
0 Sell
Strong Buy
21.26% Upside
Current: 119.170
Low
115.00
Averages
144.50
High
170.00
21.26% Upside
Current: 119.170
Low
115.00
Averages
144.50
High
170.00
Canaccord
Buy
maintain
$142 -> $147
2025-10-30
Reason
Canaccord
Price Target
$142 -> $147
2025-10-30
maintain
Buy
Reason
Canaccord raised the firm's price target on TransMedics to $147 from $142 and keeps a Buy rating on the shares. The firm said they delivered revenue in line with the firm's estimates, but slightly short of consensus which may present an interesting buying opportunity. Given the expectation for a seasonally slow and relatively in-line quarter, they believe their thesis is intact and believe any dip in the stock price creates a buying opportunity for longer-term investors,
Piper Sandler
Matt O'Brien
Overweight
downgrade
$145 -> $140
2025-10-30
Reason
Piper Sandler
Matt O'Brien
Price Target
$145 -> $140
2025-10-30
downgrade
Overweight
Reason
Piper Sandler analyst Matt O'Brien lowered the firm's price target on TransMedics to $140 from $145 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that landed just shy of consensus on the top line but handily beat on the bottom-line. Despite the revenue performance, management raised the midpoint of its full-year sales guidance based on business momentum and the nice Q4 start seen in October. Piper thinks the FY25 sales and OM outlook is conservative and should deliver upside to end the year.
Needham
Hold
to
Buy
upgrade
$148
2025-10-23
Reason
Needham
Price Target
$148
2025-10-23
upgrade
Hold
to
Buy
Reason
Needham upgraded TransMedics to Buy from Hold with a $148 price target. Needham's transplant tracker indicates that TransMedics' U.S. sales are likely to beat consensus in Q3, the analyst tells investors in a research note. The firm also expects the company's new heart and lung clinical trials and its international expansion to become growth drivers in 2026. Meanwhile, TransMedics' margins are "increasing rapidly," which should drive upside to earnings estimates, contends the analyst. Needham thinks the company "has a significant lead in a still significantly underpenetrated market."
Evercore ISI
Outperform
initiated
$155
2025-09-16
Reason
Evercore ISI
Price Target
$155
2025-09-16
initiated
Outperform
Reason
Evercore ISI initiated coverage of TransMedics with an Outperform rating and $155 price target. There is a misunderstanding among investors that the cost of TransMedics' services are materially higher than competitive alternatives, but the firm's analysis shows total costs are similar, despite materially better patient outcomes, the analyst tells investors. The firm cites the company's "differentiated" end-to-end organ transplant offering and "impressive financial outlook" for its Outperform rating on TransMedics.
Stifel
Hold
initiated
$115
2025-09-03
Reason
Stifel
Price Target
$115
2025-09-03
initiated
Hold
Reason
Stifel initiated coverage of TransMedics with a Hold rating and $115 price target. The firm would characterize results of its survey of 19 U.S. transplant surgeons survey as "mixed," reporting surgeon feedback suggests TransMedics' OCS portable organ perfusion, optimization, and monitoring system may face market share pressure, driven by competition. When factoring in the mixed survey findings, the firm believe risk-reward is balanced at current levels against its "confidence in meaningful upside potential to estimates," the analyst tells investors.
Canaccord
William Plovanic
Buy
maintain
$129 -> $142
2025-07-15
Reason
Canaccord
William Plovanic
Price Target
$129 -> $142
2025-07-15
maintain
Buy
Reason
Canaccord analyst William Plovanic raised the firm's price target on TransMedics to $142 from $129 and keeps a Buy rating on the shares. The firm updated its model to reflect their findings where they identified potential revenue upside of about 6%-10% and tightened up their historical revenue model as well. In our updated revenue model, they recalculated the components of the company's service revenues (NOP and logistics) for each organ, but the total revenues per organ have not changed. The company has a rare combination of revenue and earnings growth for a company of this market cap.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Transmedics Group Inc (TMDX.O) is 44.64, compared to its 5-year average forward P/E of -10.30. For a more detailed relative valuation and DCF analysis to assess Transmedics Group Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-10.30
Current PE
44.64
Overvalued PE
77.15
Undervalued PE
-97.75
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-6.08
Current EV/EBITDA
26.49
Overvalued EV/EBITDA
89.64
Undervalued EV/EBITDA
-101.81
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Overvalued
5Y Average PS
11.59
Current PS
119.17
Overvalued PS
22.71
Undervalued PS
0.47
Financials
Annual
Quarterly
FY2025Q3
YoY :
+32.24%
143.82M
Total Revenue
FY2025Q3
YoY :
+493.93%
23.30M
Operating Profit
FY2025Q3
YoY :
+476.83%
24.32M
Net Income after Tax
FY2025Q3
YoY :
+400.00%
0.60
EPS - Diluted
FY2025Q3
YoY :
-249.83%
61.95M
Free Cash Flow
FY2025Q3
YoY :
+5.17%
58.74
Gross Profit Margin - %
FY2025Q3
YoY :
-170.88%
21.30
FCF Margin - %
FY2025Q3
YoY :
+335.82%
16.91
Net Margin - %
FY2025Q3
13.32
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
540.3K
USD
1
3-6
Months
615.9K
USD
2
6-9
Months
1.6M
USD
4
0-12
Months
180.3K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
2
2.0M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
241.6K
Volume
2
0-12
Months
466.5K
Volume
3
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
5
1.3M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
540.3K
USD
1
3-6
Months
615.9K
USD
2
6-9
Months
1.6M
USD
4
0-12
Months
180.3K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
2
2.0M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TMDX News & Events
Events Timeline
2025-09-26 (ET)
2025-09-26
16:09:41
TransMedics and Mercedes-Benz Collaborate on Organ Transport Services in Italy
2025-09-22 (ET)
2025-09-22
05:14:09
TransMedics Partners with Mercedes-Benz Group for Organ Transport Services in Italy
2025-09-18 (ET)
2025-09-18
15:58:54
TD Cowen: TransMedics to Gain from New HHS Organ Oversight
Sign Up For More Events
Sign Up For More Events
News
5.0
10-31PRnewswireTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8.0
10-30NASDAQ.COMSignificant Thursday Options Trading: AES, ABBV, TMDX
6.0
10-30BenzingaPiper Sandler Keeps Overweight Rating on TransMedics Group, Reduces Price Target to $140
Sign Up For More News
People Also Watch
EVCM
EverCommerce Inc
9.350
USD
-19.33%
INSW
International Seaways Inc
53.310
USD
+1.79%
IDYA
IDEAYA Biosciences Inc
30.240
USD
+1.31%
WGS
GeneDx Holdings Corp
139.730
USD
+0.74%
ROCK
Gibraltar Industries Inc
61.540
USD
+3.34%
ALGT
Allegiant Travel Co
70.890
USD
+2.87%
CIFR
Cipher Mining Inc
20.690
USD
-4.70%
VYX
NCR Voyix Corp
10.910
USD
+2.06%
PSEC
Prospect Capital Corp
2.740
USD
+7.45%
KMT
Kennametal Inc
26.260
USD
+0.77%
FAQ
What is Transmedics Group Inc (TMDX) stock price today?
The current price of TMDX is 119.17 USD — it has decreased -4.65 % in the last trading day.
What is Transmedics Group Inc (TMDX)'s business?
What is the price predicton of TMDX Stock?
What is Transmedics Group Inc (TMDX)'s revenue for the last quarter?
What is Transmedics Group Inc (TMDX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Transmedics Group Inc (TMDX)'s fundamentals?
How many employees does Transmedics Group Inc (TMDX). have?